Research name and medicine brand
SS-31 is a research name associated with elamipretide. Forzinity is a specific prescription product containing elamipretide. Keeping these names connected but distinct prevents two mistakes: overlooking a genuine medicine approval, and assuming that every supplier vial using a related name is the approved product.
A defined FDA decision
FDA records identify Forzinity’s September 2025 accelerated approval for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg. The approval has a defined condition and population. The label explains the intermediate endpoint and the role of confirmatory evidence. It is not a general anti-ageing authorisation.
Why the evidence boundary matters
A rare-disease medicine record cannot be transferred to an unspecified research preparation or a different intended use. Product formulation, quality controls and clinical evidence belong to the actual approved presentation. The structural reference for elamipretide and the package artwork for Forzinity therefore have different purposes in our library.
Read future updates precisely
When an approval is conditional on further evidence, later coverage should identify the exact new study or regulatory action. Do not describe a planned confirmatory result as completed. PeptideC dates this explainer when authored and preserves the historical decision date in the text; it does not backdate the article to the approval.
Explore the references
SS-31 / elamipretide — identity, evidence and product context ↗Forzinity — identity, evidence and product context ↗Sources & references
- SS-31 / elamipretide — PubChem chemical reference, CID 11764719 ↗
- FDA — Forzinity drug trial snapshot and approval context ↗
- Forzinity — official product label, DailyMed / NLM ↗
A chemical record identifies a reference, a study reports a defined investigation, and a product label concerns a specific medicine. A supplier catalogue is not clinical evidence.
General education, not personal medical advice. Ask an appropriately qualified professional about a medicine, symptom or treatment question.